17-β Oestradiol prevents cardiovascular dysfunction in post-menopausal metabolic syndrome by affecting SIRT1/AMPK/H3 acetylation

British Journal of Pharmacology

Volumn 170, Issue 4, 2013, Pages 779-795

  Bendale, Dhaval Sharad ^a   Karpe, Pinakin Arun ^a   Chhabra, Richa ^a   Shete, Sachin Prabhakarrao ^a   Shah, Heta ^a   Tikoo, Kulbhushan ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

AMPK; post menopausal metabolic syndrome; SIRT1

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; CHEMICAL AGENT; COMPOUND C; ESTRADIOL; HISTONE H3; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAX; SIRTINOL; SIRTUIN 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARDIOVASCULAR DYSFUNCTION; CONTROLLED STUDY; DOWN REGULATION; ENDOTHELIAL DYSFUNCTION; FEMALE; HEART; HISTONE ACETYLATION; METABOLIC SYNDROME X; MUSCLE ISOMETRIC CONTRACTION; NONHUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; VASCULAR RING; VASODILATATION;

AMPK; POST-MENOPAUSAL METABOLIC SYNDROME; SIRT1;

ACETYLATION; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; AORTA; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CARDIOMYOPATHIES; CHROMATIN ASSEMBLY AND DISASSEMBLY; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HISTONES; INSULIN RESISTANCE; METABOLIC SYNDROME X; MYOCYTES, CARDIAC; NITRIC OXIDE SYNTHASE TYPE III; OVARIECTOMY; POLY(ADP-RIBOSE) POLYMERASES; POSTMENOPAUSE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ANGIOTENSIN, TYPE 1; SIGNAL TRANSDUCTION; SIRTUIN 1; TIME FACTORS; VASOCONSTRICTION; VASODILATION;

EID: 84885125282     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12290     Document Type: Article

References (72)

1. Alcendor RR, Kirshenbaum LA, Imai S, Vatner SF, Sadoshima J, (2004). Silent information regulator 2, a longevity factor and class III histone deacetylase, is an essential endogenous apoptosis inhibitor in cardiac myocytes. Circ Res 95: 971-980.
2. Alexander SPH, Mathie A, Peters JA, (2011). Guide to receptors and channels (GRAC) 5th edition. Br J Pharmacol 164: S1-S324.
3. 1 receptors and L-type calcium channels: functional coupling in supersensitivity to angiotensin II in diabetic rats. Cardiovasc Res 65: 374-386.
4. Backs J, Olson EN, (2006). Control of cardiac growth by histone acetylation/deacetylation. Circ Res 98: 15-24.
5. Bebo BF, Fyfe-Johnson A, Adlard K, Beam AG, Vandenbark AA, Offner H, (2001). Low-dose estrogen therapy ameliorates experimental autoimmune encephalomyelitis in two different inbred mouse strains. J Immunol 166: 2080-2089.
6. Berdasco M, Esteller M, (2011). Hot topics in epigenetic mechanisms of aging: 2011. Aging Cell 11: 181-186.
7. Bhuiyan MS, Fukunaga K, (2010). Characterization of an animal model of postmenopausal cardiac hypertrophy and novel mechanisms responsible for cardiac decompensation using ovariectomized pressure-overloaded rats. Menopause 17: 213-221.
8. Bitar MS, Wahid S, Mustafa S, Al-Saleh E, Dhaunsi GS, Al-Mulla F, (2005). Nitric oxide dynamics and endothelial dysfunction in type 2 model of genetic diabetes. Eur J Pharmacol 511: 53-64.
9. Borgdorff V, Rix U, Winter GE, Gridling M, Muller AC, Breitwieser FP, et al. (2013). A chemical biology approach identifies AMPK as a modulator of melanoma oncogene MITF. Oncogene. doi: 10.1038/onc.2013.
10. Cai H, Harrison DG, (2000). Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 87: 840-844.
11. Camporez J, Jornayvaz F, Lee H-Y, Kanda S, Guigni BA, Kahn M, et al. (2013). Cellular mechanism by which estradiol protects female ovariectomized mice from high-fat diet-induced hepatic and muscle insulin resistance. Endocrinology 154: 1021-1028.
12. Chambliss KL, Shaul PW, (2002). Estrogen modulation of endothelial nitric oxide synthase. Endocrine Rev 23: 665-686.
13. Chen Z, Yuhanna IS, Galcheva-Gargova Z, Karas RH, Mendelsohn ME, Shaul PW, (1999). Estrogen receptor alpha mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen. J Clin Invest 103: 401-406.
14. Cheng Z, Pang T, Gu M, Gao A-H, Xie C-M, Li, J-Y, et al. (2006). Berberine-stimulated glucose uptake in L6 myotubes involves both AMPK and p38 MAPK. Biochim Biophys Acta (BBA)-Gen Subj 1760: 1682-1689.
15. Colditz GA, Willett, WC, Stampfer, MJ, Rosner, B, Speizer, FE, Hennekens, CH, (1987). Menopause and the risk of coronary heart disease in women. N Engl J Med 316: 1105-1110.
16. Donato AJ, Magerko KA, Lawson BR, Durrant JR, Lesniewski LA, Seals DR, (2011). SIRT1 and vascular endothelial dysfunction with ageing in mice and humans. J Physiol 589: 4545-4554.
17. Dyck JRB, Lopaschuk GD, (2006). AMPK alterations in cardiac physiology and pathology: enemy or ally? J Physiol 574: 95-112.
18. Fabris B, Candido R, Bortoletto M, Toffoli B, Bernardi S, Stebel M, et al. (2011). Stimulation of cardiac apoptosis in ovariectomized hypertensive rats: potential role of the renin angiotensin system. J Hypertens 29: 273-281.
19. Gaikwad A, Gupta J, Tikoo K, (2010). Epigenetic changes and alteration of Fbn1 and Col3A1 gene expression under hyperglycaemic and hyperinsulinaemic conditions. Biochem J 432: 333-341.
20. Gibbons GH, (1997). Endothelial function as a determinant of vascular function and structure: a new therapeutic target. Am J Cardiol 79: 3-8.
21. Gorres BK, Bomhoff GL, Gupte AA, Geiger PC, (2010). Altered estrogen receptor expression in skeletal muscle and adipose tissue of female rats fed a high-fat diet. J Appl Physiol 110: 1046-1053.
22. Gupta J, Gaikwad AB, Tikoo K, (2010). Hepatic expression profiling shows involvement of PKC epsilon, DGK eta, Tnfaip, and Rho kinase in type 2 diabetic nephropathy rats. J Cell Biochem 111: 944-954.
23. Haberland M, Montgomery RL, Olson EN, (2009). The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet 10: 32-42.
24. Han Y, Li X, Zhou S, Meng G, Xiao Y, Zhang W, et al. (2012). 17β-estradiol antagonizes the down-regulation of ERα/NOS-3 signaling in vascular endothelial dysfunction of female diabetic rats. PLoS One 7: e50402.
25. Harman SM, Brinton EA, Cedars M, Lobo R, Manson JE, Merriam GR, et al. (2005a). KEEPS: the Kronos early estrogen prevention study. Climacteric 8: 3-12.
26. Harman SM, Naftolin F, Brinton EA, Judelson DR, (2005b). Is the estrogen controversy over? Deconstructing the Women's Health Initiative study: a critical evaluation of the evidence. Ann N Y Acad Sci 1052: 43-56.
27. Herrington DM, Reboussin DM, Brosnihan KB, Sharp PC, Shumaker SA, Snyder TE, et al. (2000). Effects of estrogen replacement on the progression of coronary artery atherosclerosis. N Engl J Med 343: 522-529.
28. Ho JE, Mosca L, (2002). Postmenopausal hormone replacement therapy and atherosclerosis. Curr Atheroscler Rep 4: 387-395.
29. 2 receptors. J Hypertens 30: 132-146.
30. Katz SD, (1997). Mechanisms and implications of endothelial dysfunction in congestive heart failure. Curr Opin Cardiol 12: 259-264.
31. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). NC3Rs Reporting Guidelines Working Group. Br J Pharmacol 160: 1577-1579.
32. Lee CG, Carr MC, Murdoch SJ, Mitchell E, Woods NF, Wener MH, et al. (2009). Adipokines, inflammation, and visceral adiposity across the menopausal transition: a prospective study. J Clin Endocrinol Metab 94: 1104-1110.
33. Li E, (2002). Chromatin modification and epigenetic reprogramming in mammalian development. Nat Rev Genet 3: 662-673.
34. Liou CM, Yang AL, Kuo CH, Tin H, Huang CY, Lee SD, (2010). Effects of 17beta-estradiol on cardiac apoptosis in ovariectomized rats. Cell Biochem Funct 28: 521-528.
35. Luciana V, Mark W, Wenceslau CF, Al-abri M, Cobb C, Austin AC, (2011). Acute simvastatin increases endothelial nitric oxide synthase phosphorylation via AMP-activated protein kinase and reduces contractility of isolated rat mesenteric resistance arteries. Clin Sci 121: 449-458.
36. McFarlane SI, Banerji M, Sowers JR, (2001). Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab 86: 713-718.
37. Manson JE, (2013). The kronos early estrogen prevention study. Womens Health 9: 9-11.
38. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, et al. (2003). Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 349: 523-534.
39. Manson JE, Bassuk SS, Harman SM, Brinton EA, Cedars MI, Lobo R, et al. (2006). Postmenopausal hormone therapy: new questions and the case for new clinical trials. Menopause 13: 139-147.
40. Mattagajasingh I, Kim CS, Naqvi A, Yamamori T, Hoffman TA, Jung SB, et al. (2007). SIRT1 promotes endothelium-dependent vascular relaxation by activating endothelial nitric oxide synthase. Proc Natl Acad Sci U S A 104: 14855-14860.
41. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
42. Meijer RI, Bakker W, Alta C-LAF, Sipkema P, Yudkin JS, Viollet B, et al. (2013). Perivascular adipose tissue control of insulin-induced vasoreactivity in muscle is impaired in db/db Mice. Diabetes 62: 590-598.
43. Miller VM, Clarkson TB, Harman SM, Brinton EA, Cedars M, Lobo R, et al. (2005). Women, hormones, and clinical trials: a beginning, not an end. J Appl Physiol 99: 381-383.
44. Mittal G, Chandraiah G, Ramarao P, Ravi Kumar MNV, (2009). Pharmacodynamic evaluation of oral estradiol nanoparticles in estrogen deficient (ovariectomized) high-fat diet induced hyperlipidemic rat model. Pharm Res 26: 218-223.
45. Mount PF, Kemp BE, Power DA, (2007). Regulation of endothelial and myocardial NO synthesis by multi-site eNOS phosphorylation. J Mol Cell Cardiol 42: 271-279.
46. Nishida M, Ogushi M, Suda R, Toyotaka M, Saiki S, Kitajima N, et al. (2011). Heterologous down-regulation of angiotensin type 1 receptors by purinergic P2Y2 receptor stimulation through S-nitrosylation of NF-kB. Proc Natl Acad Sci U S A 108: 6662-6667.
47. Paravicini TM, Touyz RM, (2006). Redox signaling in hypertension. Cardiovasc Res 71: 247-258.
48. Pelzer T, Jazbutyte V, Hu K, Segerer S, Nahrendorf M, Nordbeck P, et al. (2005). The estrogen receptor-alpha agonist 16 alpha-LE2 inhibits cardiac hypertrophy and improves hemodynamic function in estrogen-deficient spontaneously hypertensive rats. Cardiovasc Res 67: 604-612.
49. Peng IC, Chen Z, Sun W, Li Y-S, Marin TL, Hsu P-H, et al. (2012). Glucagon regulates ACC activity in adipocytes through the CAMKKβ/AMPK pathway. Am J Physiol Endocrinol Metab 302: E1560-E1568.
50. Pirola L, Balcerczyk A, Okabe J, El-Osta A, (2010). Epigenetic phenomena linked to diabetic complications. Nat Rev Endocrinol 6: 665-675.
51. Price NL, Gomes AP, Ling AJY, Duarte FV, Martin-Montalvo A, North BJ, et al. (2012). SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab 15: 675-690.
52. Puddu P, Puddu GM, Zaca F, Muscari A, (2000). Endothelial dysfunction in hypertension. Acta Cardiol 55: 221-232.
53. Qin F, Patel R, Yan C, Liu W, (2006). NADPH oxidase is involved in angiotensin II-induced apoptosis in H9C2 cardiac muscle cells: effects of apocynin. Free Radic Biol Med 40: 236-246.
54. Rajagopalan S, Kurz S, Manzel T, Tarpey M, Freeman BA, Griendling KK, et al. (1996). Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 97: 1916-1923.
55. Riant E, Waget A, Cogo H, Arnal J-F, Burcelin R, Gourdy P, (2009). Estrogens protect against high-fat diet-induced insulin resistance and glucose intolerance in mice. Endocrinology 150: 2109-2117.
56. Rossi R, Grimaldi T, Origliani G, Fantini G, Coppi F, Modena MG, (2002). Menopause and cardiovascular risk. Pathophysiol Haemost Throm 32: 325-328.
57. Rossig L, Li H, Fisslthaler B, Urbich C, Fleming I, Frastermann U, et al. (2002). Inhibitors of histone deacetylation downregulate the expression of endothelial nitric oxide synthase and compromise endothelial cell function in vasorelaxation and angiogenesis. Circ Res 91: 837-844.
58. Russell RR, Li J, Coven DL, Pypaert M, Zechner C, Palmeri M, et al. (2004). AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury. J Clin Invest 114: 495-503.
59. Rutter MK, Parise H, Benjamin EJ, Levy D, Larson MG, Meigs JB, et al. (2003). Impact of glucose intolerance and insulin resistance on cardiac structure and function. Circulation 107: 448-454.
60. Sahar S, Reddy MA, Wong C, Meng L, Wang M, Natarajan R, (2007). Cooperation of SRC-1 and p300 with NF-κB and CREB in angiotensin II-induced IL-6 expression in vascular smooth muscle cells. Arter Throm Vasc Biol 27: 1528-1534.
61. Seshiah PN, Weber DS, Rocic P, Valppu L, Taniyama Y, Griendling KK, (2002). Angiotensin II stimulation of NAD (P) H oxidase activity. Circ Res 91: 406-413.
62. Soloaga A, Thomson S, Wiggin GR, Rampersaud N, Dyson MH, Hazzalin CA, et al. (2003). MSK2 and MSK1 mediate the mitogen-and stress-induced phosphorylation of histone H3 and HMG-14. EMBO J 22: 2788-2797.
63. Tikoo K, Meena RL, Kabra DG, Gaikwad AB, (2008). Change in post-translational modifications of histone H3, heat shock protein 27 and MAP kinase p38 expression by curcumin in streptozotocin-induced type I diabetic nephropathy. Br J Pharmacol 153: 1225-1231.
64. Tominaga K, Yamauchi A, Egawa T, Tanaka R, Kawahara S, Shuto H, et al. (2011). Vascular dysfunction and impaired insulin signaling in high-fat diet fed ovariectomized mice. Microvasc Res 82: 171-176.
65. Touyz RM, El Mabrouk M, He G, Wu XH, Schiffrin EL, (1999). Mitogen-activated protein/extracellular signal regulated kinase inhibition attenuates angiotensin II mediated signaling and contraction in spontaneously hypertensive rat vascular smooth muscle cells. Circ Res 84: 505-515.
66. Vikram A, Jena G, Ramarao P, (2010). Pioglitazone attenuates prostatic enlargement in diet-induced insulin-resistant rats by altering lipid distribution and hyperinsulinaemia. Br J Pharmacol 161: 1708-1721.
67. Viswanad B, Srinivasan K, Kaul CL, Ramarao P, (2006). Effect of tempol on altered angiotensin II and acetylcholine-mediated vascular responses in thoracic aorta isolated from rats with insulin resistance. Pharmacol Res 53: 209-215.
68. Wang CCL, Goalstone ML, Draznin B, (2004). Molecular mechanisms of insulin resistance that impact cardiovascular biology. Diabetes 53: 2735-2740.
69. Wang Y, Huang S, Sah VP, Ross JJ, Brown JH, Han J, et al. (1998). Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated protein kinase family. J Bio Chem 273: 2161-2168.
70. Yue TL, Bao W, Gu JL, Cui J, Tao L, Ma XL, et al. (2005). Rosiglitazone treatment in Zucker diabetic fatty rats is associated with ameliorated cardiac insulin resistance and protection from ischemia/reperfusion-induced myocardial injury. Diabetes 54: 554-562.
71. Zhang Y, Lee TS, Kolb EM, Sun K, Lu X, Sladek FM, et al. (2006). AMP-activated protein kinase is involved in endothelial NO synthase activation in response to shear stress. Arterioscler Thromb Vasc Biol 26: 1281-1287.
72. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, et al. (2001). Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108: 1167-1174.